Lesinurad
FDA-approved product (tablet, oral), marketed as Zurampic.
- Registered studies
- 22
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Gout
- Hyperuricemia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Preparations increasing uric acid excretion
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA45.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli49.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae26.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis48.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
22registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Lesinurad with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Abiraterone AcetateExisting use: Cancer, Metastatic prostate cancer, Neoplasm and 3 more62.1% AI-predicted activityagainst MRSA50+ registered studies
- TicagrelorExisting use: Acute coronary syndrome, Acute myocardial infarction, Coronary artery disease and 6 more62.1% AI-predicted activityagainst MRSA50+ registered studies
- Edoxaban TosylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 3 more62.1% AI-predicted activityagainst MRSA22 registered studies
- CrizotinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma62.0% AI-predicted activityagainst MRSA50+ registered studies
- Montelukast SodiumExisting use: Airway obstruction, Allergic rhinitis, Asthma and 2 more62.0% AI-predicted activityagainst MRSA50+ registered studies
- GrazoprevirExisting use: Chronic hepatitis C virus infection61.9% AI-predicted activityagainst MRSA50+ registered studies
- Octreotide AcetateExisting use: Acromegaly, Carcinoid tumor, Metastasis and 1 more61.7% AI-predicted activityagainst MRSA50+ registered studies
- CyclosporineExisting use: Conjunctivitis, Corneal disease, Eye disease and 6 more61.7% AI-predicted activityagainst MRSA50+ registered studies
- AnidulafunginExisting use: Candidemia, Candidiasis, Peritonitis61.6% AI-predicted activityagainst MRSA43 registered studies
- Triptorelin PamoateExisting use: Central precocious puberty, Metastatic prostate cancer, Neoplasm and 3 more61.6% AI-predicted activityagainst MRSA50+ registered studies
- Vinblastine SulfateExisting use: Classic Hodgkin lymphoma, Fungal infectious disease, Hodgkins lymphoma and 3 more61.5% AI-predicted activityagainst MRSA50+ registered studies
- Lenacapavir SodiumExisting use: HIV infection, HIV-1 infection, Viral disease61.5% AI-predicted activityagainst MRSANo documented evidence found
Registered studies
A registration describes a study; it does not establish a positive result.
Open-Label Lesinurad Monotherapy Extension Study in Gout
NCT01650246 · start 2012-08
Registered record
- Registry ID
- NCT01650246
- Conditions
- Gout
- Interventions
- lesinurad
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-08
- Completion
- 2014-08
- Enrolment
- 143
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGoutInterventionlesinuradPhasePhase 3Registry statusCompletedLesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
NCT01508702 · start 2012-01
Registered record
- Registry ID
- NCT01508702
- Conditions
- Gout
- Interventions
- lesinurad; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-01
- Completion
- 2013-11
- Enrolment
- 214
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGoutInterventionlesinurad; PlaceboPhasePhase 3Registry statusCompletedCombining Lesinurad With Allopurinol in Inadequate Responders
NCT01510158 · start 2012-01
Registered record
- Registry ID
- NCT01510158
- Conditions
- Gout
- Interventions
- Lesinurad; Lesinurad; Placebo; Allopurinol; Allopurinol; Allopurinol
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-01
- Completion
- 2014-08
- Enrolment
- 607
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGoutInterventionLesinurad; Lesinurad; Placebo; Allopurinol +2 morePhasePhase 3Registry statusCompletedCombination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat
NCT01510769 · start 2012-01
Registered record
- Registry ID
- NCT01510769
- Conditions
- Tophaceous Gout
- Interventions
- Lesinurad; Lesinurad; Placebo; Febuxostat
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-01
- Completion
- 2014-06
- Enrolment
- 330
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTophaceous GoutInterventionLesinurad; Lesinurad; Placebo; FebuxostatPhasePhase 3Registry statusCompletedCombining Lesinurad With Allopurinol in Inadequate Responders
NCT01493531 · start 2011-12
Registered record
- Registry ID
- NCT01493531
- Conditions
- Gout
- Interventions
- Lesinurad; Lesinurad; Placebo; Allopurinol
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2011-12
- Completion
- 2014-07
- Enrolment
- 610
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGoutInterventionLesinurad; Lesinurad; Placebo; AllopurinolPhasePhase 3Registry statusCompletedAllopurinol Combination Study
NCT01001338 · start 2009-10
Registered record
- Registry ID
- NCT01001338
- Conditions
- Gout
- Interventions
- RDEA594; Placebo; Allopurinol
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2009-10
- Completion
- 2016-08
- Enrolment
- 227
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGoutInterventionRDEA594; Placebo; AllopurinolPhasePhase 2Registry statusCompletedGout Dose Response Study
NCT00955981 · start 2009-07
Registered record
- Registry ID
- NCT00955981
- Conditions
- Hyperuricemia
- Interventions
- RDEA594; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2009-07
- Completion
- 2011-09
- Enrolment
- 123
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHyperuricemiaInterventionRDEA594; PlaceboPhasePhase 2Registry statusCompleted